Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01871311 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
A Phase 1 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01871311 is a Phase 1 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 15 participants.
The verdict
NCT01871311, a Phase 1 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the recommended Phase II dose of nilotinib when used in combination with cetuximab in the treatment of patients with recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck.
Interventions
- DRUG Nilotinib + Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01871311
The ClinicalTrials.gov registry entry for NCT01871311 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nilotinib + Cetuximab is the first listed.
NCT01871311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01871311 about?
NCT01871311 is a clinical study titled "A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors". The purpose of this study is to determine the recommended Phase II dose of nilotinib when used in combination with cetuximab in the treatment of patients with recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck.
What is the current status of trial NCT01871311?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-05. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01871311?
The interventions under investigation include: Nilotinib + Cetuximab (DRUG).
Who is sponsoring clinical trial NCT01871311?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.